Drug Type Small molecule drug |
Synonyms Taminadenant, NIR 178, PBF-509 + [1] |
Target |
Action antagonists |
Mechanism A2aR antagonists(Adenosine A2a receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC10H8BrN7 |
InChIKeyATFXVNUWQOXRRU-UHFFFAOYSA-N |
CAS Registry1337962-47-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | United States | 28 Aug 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Japan | 28 Aug 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Argentina | 28 Aug 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Australia | 28 Aug 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Austria | 28 Aug 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Belgium | 28 Aug 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Czechia | 28 Aug 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | France | 28 Aug 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Germany | 28 Aug 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Italy | 28 Aug 2017 |
Phase 2 | Triple Negative Breast Cancer ER Negative | PR Negative | HER2 Negative | 30 | vsybdsmips(qdqxdsxjud) = mhosznuzqv quckaxrgfo (zgalutmfag ) View more | Positive | 08 Dec 2022 | ||
NCT03549000 (AACR2022) Manual | Phase 1 | 105 | NZV930(60-1000 mg Q2W) or NZV930(200-600 mg Q2W) + spartalizumab (400 mg Q4W) or NZV930(200-600 mg Q2W) + taminadenant (80-240 mg Q2W) or NZV930(200-600 mg Q2W) + spartalizumab (400 mg Q4W) + taminadenant (80-240 mg BID) | qccsfufuix(yjevrpwlsf) = ustklwkkhv cwagagkqlq (ljykndfqih ) View more | Positive | 08 Apr 2022 | |
Phase 1 | 25 | vegxqggeot(qarvpcvgdv) = Dose-limiting toxicities (all Grade 3) with taminadenant alone were alanine/aspartate aminotransferase increase and nausea (n=1 [4.0%] each; 640 mg) and in the combination group were pneumonitis (n=2 [8.0%]; 160 and 240 mg), fatigue and alanine/aspartate aminotransferase increase (n=1 [4.0%] each; 320 mg); pneumonitis cases responded to steroids rapidly and successfully. tfvurrpsot (dnjiopmnxl ) | - | 07 Mar 2022 | |||
Taminadenant with Spartalizumab | |||||||
Phase 2 | Metastatic Microsatellite Stable Colorectal Carcinoma Microsatellite Stable (MSS) | 58 | dgjxctvlcd(rlcojmxmzv) = cezhcrtitr mcsbsdcnhh (scytbixbvh, 0.0 - 9.2) View more | Positive | 16 Sep 2021 | ||
Phase 1/2 | Non-Small Cell Lung Cancer Second line | 24 | tqpzawmchs(mfpfinquwl) = none acsmbepnew (ehxtuavqgj ) View more | Positive | 03 Jun 2018 |